Business Context and Reporting Period
This Form 8-K filing by Miragen Therapeutics, Inc. (trading symbol: MGEN) reports events occurring on February 12, 2020, with the report filed on February 19, 2020. The company is a Delaware corporation focused on developing therapeutic candidates, specifically Cobomarsen for certain cancers and MRG-229 for fibrosis.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements approved on February 12, 2020.
Material Changes and Executive Compensation
The Board of Directors approved significant changes to executive compensation, including new stock option grants and 2020 base salary/bonus targets.
Stock Option Grants
Options were granted to three Executive Officers under the 2016 Equity Incentive Plan with an exercise price of $0.795 per share (closing price on the grant date). Vesting is structured as follows:
- 50% vests in 48 equal monthly installments starting March 12, 2020.
- 25% vests upon completion of a Cobomarsen development milestone.
- 25% vests upon completion of an MRG-229 development milestone.
Options expire ten years after the grant date and are subject to accelerated vesting upon a change of control or specific termination events.
| Executive Officer | Position | Shares Subject to Option |
|---|---|---|
| William S. Marshall, Ph.D. | President and CEO | 464,000 |
| Jason A. Leverone | CFO, Secretary, Treasurer | 185,000 |
| Diana Escolar, M.D. | Chief Medical Officer | 270,000 |
2020 Base Salary and Bonus Targets
The Board approved the following 2020 compensation packages. Bonus targets are percentages of base salary and contingent on corporate and individual performance goals.
| Executive Officer | 2020 Base Salary | Bonus Target |
|---|---|---|
| William S. Marshall, Ph.D. | $536,600 | 50% |
| Jason A. Leverone | $365,700 | 40% |
| Diana Escolar, M.D. | $415,000 | 40% |
Outlook, Risks, and Corporate Goals
The Board established corporate performance goals for the fiscal year ending December 31, 2020, which may be updated at the Board's discretion. Key goals include:
- Executing the development plan for Cobomarsen.
- Executing the development plan for MRG-229.
- Achieving finance and business development objectives.
Bonus payments are contingent on the executive's continuous employment on the payment date and are subject to Board discretion regarding performance achievement.
Investor Verification Checklist
- Verify the current status of the Cobomarsen and MRG-229 clinical development milestones required for option vesting.
- Review the full text of the 2016 Equity Incentive Plan and Related Agreements (Exhibits 10.37 and 10.38 to Form S-4) for detailed vesting and termination conditions.
- Monitor future filings for updates to the corporate performance goals, as the Board reserves the right to modify them during 2020.
- Confirm the company's cash position to assess its ability to fund the approved executive salaries and ongoing clinical trials.